during pregnancy depending on the maternal PROGINS progesterone receptor gene polymorphism 8 as well as the maternal peroxisome proliferator-activated receptor gamma2 Pro12Ala polymorphism. 9 The relationship between the renin-angiotensinaldosterone system (RAAS) and insulin resistance is well known. 10 Patients on antihypertensive treatment with drugs affecting the RAAS such as angiotensin converting enzyme (ACE) inhibitors and angiotensin (AT) 1 receptor blockers seem to have a lower incidence of new onset diabetes and show improved insulin sensitivity. [11] [12] [13] From animal models it is known that the application of AT 1 receptor blockers improves glucose tolerance through enhancement of insulin-mediated glucose uptake in peripheral organs like skeletal muscle, possibly due to changes in blood flow. 14 Also, changes in muscle fibre composition, decreased concentrations of tumour necrosis factor α in skeletal muscle and cross-talk in the signalling pathways of angiotensin and insulin receptors are discussed as an explanation of the observed phenomena. 10, 14 The primary goal of this study was to test the hypothesis that an interaction of fetal sex/ fetal Y/X chromosomes with the maternal ACE gene may substantially affect maternal glycaemic control during pregnancy. This hypothesis was tested in healthy women of the Berlin birth cohort. 8, 9, 15, 16 The ACE I/D polymorphism is associated with higher ACE plasma levels 17, 18 and has been linked to disease progression in diabetic nephropathy, outcome after renal transplantation and other clinical outcomes. [19] [20] [21] It seems thus to be a good candidate to test the hypothesis that maternal genetic variations within the RAAS may affect maternal glycaemic control during pregnancy depending on fetal sex/sex chromosomes.
Material and methods

Subjects and data collection
This study was approved by the local ethics committee. We invited all Caucasian women without history of pre-existing diabetes or hypertension (before the pregnancy) with singleton pregnancies delivering consecutively at the Charité obstetrics department in Berlin/Germany between June 2001 and September 2002 to participate in this study. We excluded cases where there were hints for an intersexual phenotype of the newborn at birth. 4.8% of all eligible women refused to participate. We thus could finally include 1332 remaining mother/child pairs. After obtaining written informed consent, a structured medical history was taken (for example, about pre-existing diabetes or hypertension). German guidelines for medical follow-up in pregnancy comprise the so-called 'Mutterpass' (pregnancy health document) containing essential data about the pregnancy. The data in this document were also used to judge whether the women fulfill all inclusion/exclusion criteria. The following data was extracted into our database: age, body height, weight before and during pregnancy, gravidity, parity, gestational age at delivery, urine dipstick results, evaluation of oedema and blood pressure readings at all follow-up visits. New onset of proteinuria in second half of pregnancy was defined as switch from urine dipstick negative results for protein excretion in at least two independent tests in the first half of pregnancy to urine dipstick positive results for protein excretion in at least two independents tests in the second half of pregnancy. We analysed for this purpose only dipstick measurement, if there were no signs of urine infections in the dipstick analysis (absence of blood and nitrate). Blood pressure readings at all follow-up visits in the seated position by physicians or obstetric nurses via the auscultatory method using a mercury or aneroid sphygmomanometer were included into the database (6-23 measurements depending on the number of visits). Fetal blood was collected from the umbilical cord. Midwives collected maternal blood from a cubital vein in the delivery room or on the ward. Biometric data of the newborn were routinely measured right after delivery.
Total glycated haemoglobin
Fetal and maternal blood was analysed using the highperformance liquid chromatography (HPLC)-based Variant Total Glycated Hemoglobin Testing System (Bio-Rad, Hercules, California, USA) as described recently. 16 As the system works independently of the haemoglobin type, it allowed quantifying glycosylation of fetal haemoglobin (HbF) as well as adult haemoglobin. Briefly, glycated haemoglobin was separated from non-glycated haemoglobin by boronate affinity chromatography. The separated haemoglobins were passed through a filter photometer, where changes of absorbance were measured at 415 nm. A secondary filter at 690 nm corrected for matrix effects caused by mixing buffers of different ionic strength. A calibrator was analysed with each run. No interference with labile glycated haemoglobins, lipaemia, bilirubin, temperature fluctuations or agerelated degradation was observed. The system has been certified by the National Glycohemoglobin Standardization Program (USA).
Genotyping
Genomic DNA was isolated from peripheral white blood cells and genotyping for the ACE I/D polymorphism was performed as described previously. 19 DNA-fragments were amplified using the following primers: 5′-GCCCTGCAGGTGTCTGCAGCATGT-3′ and 5′-GGATGGCTCTCCCCGCCTTGTCTC-3′. Polymerase chain reaction (PCR) yields products of 319 and 597 bp for the D and I alleles, respectively. All samples yielding amplification products of the D allele exclusively (and therefore potentially typed as DD) were subjected to a second independent amplification using primers specific for the sequence insert to intron 16 of the I allele with the following primers: 5′-TGGGACCACAGCGCCCGCCACTAC-3′ and 5′-TCGCCAGCCCTCCCATGCCCATAA-3′. PCR yields an amplification product of 355 bp only in the presence of an I allele. Only matching results from separate blinded double determinations were accepted.
Statistical analysis
For statistical analysis, the data were analysed with SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Results of continuous variables are expressed as arithmetic mean ± standard deviation (SD 
Results
Descriptive data of the study population are given in tables 2 and 3. The study population represents a typical German birth cohort with respect to key characteristics like maternal age, number of pregnancies per mother, fetal birthweight and fetal length. The maternal ACE I/D polymorphism shows a highly significant interaction with fetal sex concerning maternal total glycated haemoglobin, whereas other parameters describing maternal physiology during pregnancy (new onset proteinuria, new onset oedema as well as pregnancy-induced hypertension) did not show this interaction (table 1). The ACE I/D polymorphism-fetal sex interaction was seen in all tested models (additive model, I recessive model, D recessive model and II vs. DD model). TGH data of the mothers according to maternal ACE I/D polymorphism are given in table 3. TGH in DD mothers delivering boys was 6.42 ± 0.70% and 6.21 ± 0.66% in DD mother delivering girls (p < 0.005), whereas the II carrying mothers showed the opposite effect. II mothers delivering a girl had a higher (p = 0.044) TGH at birth (6.40 ± 0.80%) compared to II mothers delivering boys (6.21 ± 0.81%) (table 3, figure 1 ). The offspring's gender had no influence in mothers carrying the ID genotype.
Mothers delivering boys with the II genotype had a lower TGH (6.21 ± 0.81%) as compared to mother delivering also boys with the DD genotype (6.42 ± 0.70%). This differences were significant regardless the used model (table 4, figure 2 ). On the other hand, mothers delivering girls with the II genotype had a higher TGH (6.40 ± 0.80%) as compared to mother delivering also girls with the DD genotype (6.21 ± 0.66). These differences were significantly different when using the I recessive as well as the II vs. DD models.
Discussion
Our study in a Caucasian population of healthy normal pregnancies (Berlin birth cohort 8, 9, 15, 16 ) demonstrated that the maternal ACE I/D polymorphism shows a highly significant interaction with fetal sex concerning maternal TGH at delivery. TGH is an established marker that correlates significantly with both short-term and long-term antecedent glycaemia. 22 TGH is the appropriate marker of glycaemia in the presence of fetal HbF, since it also detects glycated HbF. TGH was assessed in mothers and newborns in order to get comparable results. As yet, there is no specific information on TGH levels during pregnancy in the literature. However, in our study we only looked at relative differences between groups. TGH in DD mothers delivering boys was 6.42 ± 0.70% and was 6.21 ± 0.66% in DD mother delivering girls (p < 0.005), whereas the II carrying mothers showed the opposite effect: II mothers delivering a girl had a higher (p = 0.044) TGH at birth (6.40 ± 0.80%) as compared to II mothers delivering boys (6.21 ± 0.81%). The angiotensin converting enzyme (ACE) is a zinc metallopeptidase widely distributed on the surface of endothelial and epithelial cells. It plays an essential role in two physiological systems. ACE converts the inactive decapeptide, angiotensin I (Ang I or Ang 1-10), to the active octapeptide and potent vasoconstrictor angiotensin II (Ang II or Ang 1-8), which is the main active product of the RAAS. Furthermore, ACE also plays an important role in another hormonal system, the kinin-kallikrein cascade. ACE metabolises bradykinin, which is a strong vasodilator, forming the inactive metabolite bradykinin 1-5 (for a review, see Sayed-Tabatabaei et al. 23 ). Circulating ACE levels are under substantial genetic control. The insertion/ deletion polymorphism in intron 16 is one of the beststudied polymorphism of the ACE gene. It was suggested that it might account for approximately half of the observed variance in plasma levels. The location of this polymorphism in a non-coding region of the gene, however, makes it unlikely to be a functional variant. Although the nature and location of the real functional polymorphisms responsible for plasma ACE levels remain unknown, all of the studies performed in Caucasian populations indicated that the majority of the polymorphisms in the candidate region of the ACE gene being responsible for plasma ACE concentrations are tightly linked with the I/D polymorphism. It is thus justified to use the I/D polymorphism as a valid marker for studying the associations between even unknown -functional -polymorphism(s) of the ACE gene and pathophysiological conditions (for a review, see Sayed-Tabatabaei et al. 23 ).
There are several -although rather small -studies suggesting that women carrying the D allele of the ACE-I/D polymorphism have higher ACE activity and higher measures of uterine artery resistance, which is a risk factor marker for the development of intrauterine growth retardation and pre-eclampsia. 24, 25 Thus it was suggested that the ACE I/D polymorphism might be associated with blood pressure alterations in pregnancy. The current study does not support this hypothesis. This is in line with a recent large study likewise addressing this issue. 26 The association of the ACE I/D polymorphism with hypertensive disorders in pregnancy (including pre-eclampsia) in our study population was analysed and discussed in detail in a previous publication from our group. 27 Our present study is the first to analyse glycaemic control in pregnancy in relationship to the ACE I/D polymorphism although it is well established that the RAAS plays a pivotal role in the development of insulin resistance and also type 2 diabetes. [10] [11] [12] 14 Overall, we saw no impact of the maternal ACE I/D polymorphism on glycaemic control during the last weeks of pregnancy. Based on our previous studies 8, 9 indicating that glycaemic control during pregnancy might be influenced in genetically susceptible mothers by the fetal sex/sex chromosomes, we hypothesised that this effect might be relevant for the ACE I/D polymorphism as well. Our study confirmed this concept and thus added a third gene to maternal genes that may exert effects on glycaemic control during the last weeks of pregnancy in an offspring sex-dependent manner.
A gender-dependent effect of the ACE I/D polymorphism on renal diseases as well as cardiovascular diseases was reported by others earlier. 28 The ACE DD allele, for example, was associated with disease progression in male patients with autosomal dominant polycystic kidney disease (ADPKD). Males with DD genotype developed end-stage renal disease 5 years earlier compared with males carrying the ID/II genotypes. Accordingly, the DD genotype was almost three times more frequent in the rapid vs. the slow progressors in male ADPKD patients. In females, there was no impact of the ACE I/D polymorphism detectable. 29 In a study including 3095 participants of the Framingham heart study, the DD genotype was associated with higher diastolic blood pressure in men, but not in women. In two recent, large sib-pair studies, ACE influenced systolic and diastolic blood pressure in men, but not in women. Furthermore, in mice harbouring an inactivated ACE gene, the observed decrease in blood pressure was restricted to males (for a review, see Fischer et al. 30 ).
Our study indicated that fetal sex chromosomes might modulate the effect of maternal genes on maternal glycaemic control during the last weeks of pregnancy. There is already good evidence indicating an influence of fetal genes on maternal metabolism in a rare human disease: the Beckwith-Wiedemann syndrome, 31 a syndrome caused by a mutation in the 11p15 chromosomal region of the newborn.
The traditional concept states that glycaemic control of the mother during pregnancy results from interactions between maternal genes and environment. In a recent large study, however, it was shown in 55,891 deliveries of male and 53,104 deliveries of female neonates, that pregnant women carrying male fetuses had higher rates of gestational diabetes mellitus (3433 cases, 6.1%) vs. women carrying a girl (3070 cases, 5.8%; p = 0.012). 32 The fetal sex-dependent effects of the maternal ACE gene on maternal metabolism during pregnancy might be mediated by the placenta. The placenta serves as an interphase between fetus and mother. The placenta controls the flow of nutrients to the unborn offspring and the release of placental hormones that might influence maternal metabolism. 6, 7 Fetal sex hormones might modulate the secretion of placental hormones that contribute to the maternal glycaemic control. Keeping this in mind, there are, in principle, two options to explain our findings: First, there are two independent stimuli that alter glycaemic control: male fetal gender (via secretion of placental hormones to the mother that alter glycaemic control) as well as the maternal DD genotype of the ACE gene (resulting in enhanced ACE activity thus reducing insulin sensitivity). These independent factors act in parallel on maternal glycaemic control resulting in higher total glycated haemoglobin in DD mothers carrying boys. Second, on the other hand it is also possible that both factors act synergistically, meaning that elevated ACE concentrations (in DD mothers) act directly on the secretion of placental hormones in placentas from male fetuses resulting in secretion of placental hormones/ hormone patterns that impair maternal glycaemic control.
Although our study was performed in more than 1000 subjects and the findings were very robust (seen in independent models), our study needs to be confirmed in a second independent adequately sized cohort. Furthermore, the underlying molecular mechanisms need to be addressed in future studies.
In our study population, a considerable proportion of women seems to develop proteinuria, oedema or hypertension during pregnancy. This is partly due to the fact that many women with complicated pregnancies within the Berlin area are referred to the special care of the Charité university hospital and accumulate there. Pre-eclampsia occurred in 2.4% and 2.9% developed pre-eclampsia superimposed on chronic hypertension. However, urine dipstick results were not verified by a quantitative method, so a considerable number of false positive results are to be expected. 33 The rate of oedema does not seem especially high in our study population. In other populations up to 80% of pregnant women develop peripheral oedema at some stage of their pregnancy. 34 The rate of gestational hypertension is similar to the rate observed in other large populations. 35 
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